Medical professionals have been searching for a viable treatment for Parkinson's disease for a long time. While there have been advancements and new therapies created, many patients are still looking…
In a press release by Parkinson's Canada; researchers in Canada wanted to unpack why some people first lose their sense of smell before developing Parkinson’s disease with age. While losing…
The gut plays a big role in our bodies, we know that. While some of its roles are obvious, others are still being discovered. In fact, the microbiome of the…
According to a story from Parkinson's News Today, an approach called whole-body electromyostimulation (WB-EMS) was able to benefit Parkinson's disease patients in a small scale study. These patients were not…
ACADIA Pharmaceuticals has released data on NUPLAZID, a selective serotonin inverse agonist and antagonist preferentially targeting 5-HT2A receptors. This treatment is meant to treat Parkinson's disease patients, specifically the delusions…
Medical professionals are still trying to understand all of the underlying causes of Parkinson's disease, a progressive disease that sees the degeneration and death of motor neurons. A recent study…
Over 50 years ago, levodopa was approved to treat patients with Parkinson's disease. To this day, levodopa, administered via pills or intravenously, remains the standard-of-care. But according to Parkinson's News…
According to a story from Parkinson's News Today, a small study recently demonstrated that fecal transplants could help relieve gastrointestinal problems in Parkinson's disease patients, as well as reducing the…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
